Posted by Site Administrator on January 15, 2013
“Some may look at recent failures and be discouraged,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an e-mail to Alzforum. Thanks to advances in genetics and biomarkers, and a list of potential target pathways, “I think this is a time of unprecedented hope and excitement in ALS research”
Categories: Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS clinical trials, ALS community, ALS Functional Rating Scale (ALSFRS), ALS Phase 3 studies, ALS research, ALS research funding, ALS sodium chlorite, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Angela Genge, Annual Symposium on Amyotrophic Lateral Sclerosis/Motor Neuron Disease, antisense oligonucleotide therapy ALS, astrocyte excitatory amino acid transporter 2, Benjamin Brooks, Biogen Idec, biomarkers ALS, Bob Stehlin, ceftriaxone, CK-2017357, cytochrome P450 1A2, Cytokinetics, dexpramipexole, Dr. Timothy Miller, Duke ALS Clinic Durham, Emory University Atlanta, Evan Snyder, FDA, fingolimod, Food and Drug Administration, Forbes Norris MDA/ALS Research Center, genetics ALS, Gilenya, immune-system drugs ALS, Inc., ISIS 333611, Isis Pharmaceuticals, Jeremy Shefner, Jonathan Glass, Les Turner ALS Foundation, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, mitochondrial modulator, Montréal Neurological Institute and Hospital, mutant human superoxide dismutase 1, mutant superoxide dismutase 1, Neil Cashman, Neuralstem Inc, Neuraltus, North Carolina, Northeast ALS Consortium, Novartis, NP001, olesoxime, oligonucleotide, oligonucleotide ALS, oligonucleotide via intrathecal infusion, PALS, Phase III trial ALS, Pitié-Salpêtrière Hospital, RASCALS Foundation, Richard Bedlack, riluzole, Robert A. Stehlin Campaign for ALS, Robert Brown, Robert Miller, Sanford-Burnham Medical Research Institute, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York Upstate Medical University, stem cell trial ALS, Steven Perrin, Susanna Benn, synaptic glutamate, target pathways ALS, Tim Miller, Timothée Lenglet, Tirasemtiv, troponin ALS, University of British Columbia, University of Massachusetts Medical School Worcester, University of North Carolina School of Medicine, Washington University St. Louis, Wendy Abrams, Yang Teng, Yang Teng of Brigham and Women’s Hospital
| 
No comments
Posted by Site Administrator on December 5, 2012
Cytokinetics, Incorporated announced today that a platform presentation relating to tirasemtiv is scheduled to be presented at the 23rd International Symposium on ALS/MND to be held December 5-7, 2012 at the Sheraton Chicago Hotel and Towers Hotel in Chicago, IL. The presentation will include pharmacokinetics and drug-drug interaction analyses from previously-reported clinical trials of tirasemtiv in patients with amyotrophic lateral sclerosis.
Categories: Clinical Trials, Treatments
| Tags: 23rd International Symposium on ALS/MND, ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, BENEFIT-ALS, Bob Stehlin, Cytokinetics, PALS, RASCALS Foundation, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Tirasemtiv
| No comments
Posted by Site Administrator on October 4, 2012
South San Francisco biotechnology company Cytokinetics announced Sept. 10, 2012, that it plans to conduct a new phase 2b clinical trial of its oral drug tirasemtiv (formerly CK-2017357) in people with amyotrophic lateral sclerosis (ALS). The trial is set to launch later this year.
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, CK-2017357, Cytokinetics, FDA ALS, Lou Gehrig's disease, PALS, phase 2b clinical trial tirasemtiv, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Tirasemtiv
| No comments
Posted by Site Administrator on June 19, 2012
Both patients and investigators perceived a dose-dependent benefit of CK-2017357 as measured by global impression of change. Maximum voluntary ventilation and submaximal handgrip endurance also improved.
Categories: Research News, Treatments
| Tags: ALS, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, Bob Stehlin, CK-2017357, Clinical Trial Publication of CK-2017357 in Amyotrophic Lateral Sclerosis, CY 4025, Cytokinetics, fast skeletal muscle troponin activator, FDA Fast Track designation ALS, Jeremy M. Shefner, Phase II, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Upstate Medical University at the State University of New York
| No comments
Posted by Site Administrator on December 21, 2011
CK-2017357 previously demonstrated potentially clinically relevant pharmacodynamic effects in a completed Phase IIa Evidence of Effect clinical trial in ALS patients.
Categories: Research News
| Tags: ALS, ALS community, amyotrophic lateral sclerosis, breakthrough, CK-2017357, Cytokinetics, Department of Neurology at the Upstate Medical University at the State University of New York, Lou Gehrig's disease, RASCALS Foundation
| No comments
Posted by Site Administrator on December 20, 2011
Some trial participants who were treated with the highest dose showed measurable improvement in motor function and muscle strength.
Categories: Research News
| Tags: ALS, ALS community, amyotrophic lateral sclerosis, CK-2017357, Cytokinetics, Lou Gehrig's disease, RASCALS Foundation, Robert A. Stehlin Campaign for ALS
| No comments
